May 8 (Reuters) - 3M spin-off Solventum ( SOLV ) beat

analysts' estimate for first-quarter profit on Thursday, helped

by higher sales of its wound care, sterilization products.

The Minnesota-based company is one of the largest providers

of sterilization devices, wound dressings, medical tape and

other hospital consumables used by healthcare facilities.

Solventum ( SOLV ) also raised its annual organic sales growth

forecast up 1.5% to 2.5% from prior forecast of up 1.0% to 2.0%.

The forecast includes its purification and filtration

segment, the company said.

The company's MedSurg business, which provides wound

dressings and surgical equipment, makes more than half of its

total revenue. Sales in this segment were $1.16 billion during

the quarter.

The company continues to expect annual profit per share in

the range of $5.45 to $5.65.

It reported total net sales of $2.1 billion for the quarter,

a 2.6% rise from a year earlier.

Solventum ( SOLV ) posted an adjusted profit of $1.34 per share for

the quarter ended March 31, compared with analysts' average

estimate of $1.22 per share, according to data compiled by LSEG.